DURHAM, N.C., May 29, 2015 /PRNewswire-iReach/ -- A study released today in STEM CELLS Translational Medicine could open the door to a new therapy to potentially expand the current window of time for treating patients after they have experienced a stroke (five times beyond that of a clot-busting drug) and significantly improves their chance of recovery.
You are here
Press Releases from AlphaMed Press
Embargo Policy: Articles for STEM CELLS and STEM CELLS Translational Medicine are embargoed for release until 9 a.m. Eastern U.S. time on the day the article is posted online. This policy applies to members of the media, authors, institutions' public information officers, and the public. Authors may not discuss their work with the media until 1 week before the mailing date or 1 week before online posting of the article, whichever is earlier, and must ensure that the media representatives agree to abide by the embargo policy. STEM CELLS Translational Medicine may refuse to publish a manuscript, despite acceptance for publication, if it has been prematurely released to the press.
DURHAM, N.C., May. 27, 2015 /PRNewswire-iReach/ -- A new study appearing today in STEM CELLS Translational Medicine, designed to test how stem cell injections affect primates with spinal cord injury (SCI), showed the treatments significantly improved the animals' motor function recovery and promoted faster healing, too. The researchers call their findings a step forward toward the goal of improving outcomes for humans with chronic SCI.
DURHAM, N.C., May. 1, 2015 /PRNewswire-iReach/ -- Stem cells are a safe therapy for patients with amyotrophic lateral sclerosis (ALS), according to the results of a recently completed phase 1 clinical trial. Details of the trial, conducted by scientists in South Korea, are published in this month's issue of STEM CELLS Translational Medicine.
DURHAM, NC (PRWEB) March 31, 2015 /PRWeb/ -- Stem cells may provide Crohn’s disease sufferers relief from a common, potentially dangerous side effect – fistulas – according to the results of a phase 2 clinical trial published in the latest issue of STEM CELLS Translational Medicine (SCTM). After receiving an injection of their own adipose-derived stem cells (ASC), which are collected from fat tissue, the fistulas in 75 percent of the trial participants were completely healed within eight weeks of their last treatment and remained so two years later.
DURHAM, NC (PRWEB) March 19, 2015 /PRWeb/ -- A new study appearing in STEM CELLS Translational Medicine has moved science one step closer to finding a simple treatment for erectile dysfunction (ED) after prostate cancer surgery, eschewing the usual pharmaceutical drug route with potential for harmful side effects, in favor of stem cell therapy that can help the body regenerate.
The study, conducted in rats, compares the effectiveness of using a byproduct of liposuction — uncultured stromal vascular fraction (SVF) — with adipose-derived stem cells (ADSCs) cultured in the lab to treat ED caused by injury to the cavernous nerve (CN). This nerve, which facilities erection, is sometimes injured during a radical prostatectomy to treat prostate cancer.
Scientists report in the current issue of STEM CELLS Translational Medicine that they have been able to clone a line of defective stem cells behind a rare, but devastating disease called Fanconi Anemia (FA). Their achievement opens the door to drug screening and the potential for a new, safe treatment for this often fatal disease.
FA is a hereditary blood disorder that leads to bone marrow failure (FA-BMF) and cancer. Patients who suffer from FA have a life expectancy of 33 years. Currently, a bone marrow transplant offers the only possibility for a cure. However, this treatment has many risks associated with it, especially for FA patients due to their extreme sensitivity to radiation and chemotherapy.
Several studies showing the promise of stem cells for treating patients with heart failure have made headline news recently. However, all these studies dealt with adult patients only. New research appearing in this month’s STEM CELLS Translational Medicine shows that stem cells may have the same potential in treating children with congenital heart diseases that can lead to heart failure.
The study, undertaken by researchers at the Mayo Clinic in Rochester, Minn., looked at the feasibility and long-term safety of injecting autologous umbilical cord blood cells directly into the heart muscle at the pediatric stage of heart development. The study was conducted on pigs, due to their hearts’ similarity to human hearts.
A new study published in the latest issue of STEM CELLS Translational Medicine reveals how a particular type of stem cell generated from fat tissue may outperform other types of stem cells in speeding up the healing of wounds caused by type 1 diabetes. In the study, ulcers in a mice model treated with these cells healed significantly faster than those treated with general types of stem cells.
Slow-healing wounds present one of the most common and perplexing complications associated with both type 1 and type 2 diabetes. If left untreated, they can lead to amputation, and even death. In fact, diabetes is the leading cause of non-traumatic lower limb amputation in the United States, according to the American Diabetes Association. Despite this, there are very few consistently effective treatments for speeding the wound-healing process in patients.
Recent research aimed at finding a treatment for a common form of blindness could give new meaning to the term “eye teeth.” In a study in mice published in STEM CELLS Translational Medicine, researchers at the University of Pittsburgh show how stem cells harvested from teeth extracted during routine dental procedures can potentially be used to restore sight in those suffering from corneal blindness.
Stem cells collected from placenta, which is generally discarded after childbirth, show promise as a treatment for heart failure. Found in the latest issue of STEM CELLS Translational Medicine, a new study using mice determined that human-derived adherent cells (PDAC® cells) significantly improved cardiac function when injected into the heart muscle.
Currently, about 6 million people in the United States alone suffer from heart failure, which is when the heart’s pumping power is weaker than normal. Despite intensive medical care, almost 80 percent of people die within eight years of diagnosis, making it the world’s leading cause of death. Heart failure can be the result of coronary artery disease, heart attack and other conditions such as high blood pressure and valve disease.